Key result
Toxicologic antiarrhythmic exposure in children is linked to a ~326% higher risk of PICU intervention.
Why the study?
Interventions requiring PICU are rare in toxicologic exposures, but cardiovascular medications are high-risk due to their hemodynamic effects, necessitating description of prevalence and risk factors for PICU interventions among exposed children.
What are the prevalence and risk factors for PICU interventions among children exposed to cardiovascular medications?
Cohort (n=1,091)
Yes
What are the prevalence and risk factors for PICU interventions among children exposed to cardiovascular medications?
Odds Ratio: 4.26 (95% CI 1.41–12.9)
PICU interventions are uncommon in pediatric cardiovascular medication exposures but are more likely with antiarrhythmics, calcium channel antagonists, and alpha-2 agonists, while children under 2 are less likely to require them.
Certain CV medication classes and age may inform disposition after pediatric toxicologic exposures; leaves open optimal PICU criteria pending prospective studies.
OBJECTIVES: Interventions requiring a PICU are rare in toxicologic exposures, but cardiovascular medications are high-risk exposures due to their hemodynamic effects. This study aimed to describe prevalence of and risk factors for PICU interventions among children exposed to cardiovascular medications. DESIGN: Secondary analysis of Toxicology Investigators Consortium Core Registry from January 2010 to March 2022. SETTING: International multicenter research network of 40 sites. PATIENTS: Patients 18 years old or younger with acute or acute-on-chronic toxicologic exposure to cardiovascular medications. Patients were excluded if exposed to noncardiovascular medications or if symptoms were documented as unlikely related to exposure. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: Of 1,091 patients in the final analysis, 195 (17.9%) received PICU intervention. One hundred fifty-seven (14.4%) received intensive hemodynamic interventions and 602 (55.2%) received intervention in general. Children less than 2 years old were less likely to receive PICU intervention (odds ratio [OR], 0.42; 95% CI, 0.20-0.86). Exposures to alpha-2 agonists (OR, 2.0; 95% CI, 1.11-3.72) and antiarrhythmics (OR, 4.26; 95% CI, 1.41-12.90) were associated with PICU intervention. In the sensitivity analysis removing atropine from the composite outcome PICU intervention, only exposures to calcium channel antagonists (OR, 2.12; 95% CI, 1.09-4.11) and antiarrhythmics (OR, 4.82; 95% CI, 1.57-14.81) were independently associated with PICU intervention. No independent association was identified between PICU intervention and gender, polypharmacy, intentionality or acuity of exposure, or the other medication classes studied. CONCLUSIONS: PICU interventions were uncommon but were associated with exposure to antiarrhythmic medications, calcium channel antagonists, and alpha-2 agonists. As demonstrated via sensitivity analysis, exact associations may depend on institutional definitions of PICU intervention. Children less than 2 years old are less likely to require PICU interventions. In equivocal cases, age and exposure to certain cardiovascular medication classes may be useful to guide appropriate disposition.
No takes yet. Share an insight, caveat, or question.
Simpson et al. (2023) conducted a cohort in Toxicologic exposures to cardiovascular medications (n=1,091). Toxicologic exposure to cardiovascular medications (e.g., antiarrhythmics, alpha-2 agonists) vs. Other medication classes was evaluated on PICU intervention (OR 4.26, 95% CI 1.41-12.90). Toxicologic exposure to antiarrhythmics was strongly associated with requiring PICU intervention among children (OR 4.26; 95% CI 1.41-12.90), with an overall PICU intervention rate of 17.9%.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: